TCT 2021

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

Michael Gibson and David Cohen discuss the 2-year economic outcomes of PARTNER 3 for TAVR vs. SAVR in in low surgical risk patients.

We Recommend